Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA.

N Engl J Med. 2003 Jul 31;349(5):427-34.

2.

Bevacizumab for patients with metastatic renal cancer: an update.

Yang JC.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6367S-70S. Review.

3.

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

Rini BI, Small EJ.

J Clin Oncol. 2005 Feb 10;23(5):1028-43. Epub 2004 Nov 8. Review.

PMID:
15534359
4.

[Angiogenesis and renal cell carcinoma].

Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O.

Bull Cancer. 2007 Jul;94 Spec No:S232-40. Review. French.

PMID:
17846009
5.

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.

Escudier B, Cosaert J, Pisa P.

Expert Rev Anticancer Ther. 2008 Oct;8(10):1545-57. doi: 10.1586/14737140.8.10.1545. Review.

PMID:
18925847
6.

Targeted therapy for metastatic renal cell carcinoma.

Motzer RJ, Bukowski RM.

J Clin Oncol. 2006 Dec 10;24(35):5601-8. Review.

PMID:
17158546
7.

Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.

Frampton JE, Keating GM.

BioDrugs. 2008;22(2):113-20. Review.

PMID:
18345708
8.

Immunotherapy for advanced renal cell cancer.

Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425. Review. Update in: Cochrane Database Syst Rev. 2015;12:CD001425.

PMID:
15674877
9.

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B.

Cancer Treat Rev. 2016 Nov;50:109-117. doi: 10.1016/j.ctrv.2016.09.002. Epub 2016 Sep 10. Review.

PMID:
27664394
10.
11.

Progress in the management of advanced renal cell carcinoma (RCC).

Tong TQ, Rohde D, Peter S.

Aktuelle Urol. 2010 Jan;41 Suppl 1:S57-60. doi: 10.1055/s-0030-1247237. Epub 2010 Jan 21. Review.

PMID:
20094957
12.

Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.

Golshayan AR, Brick AJ, Choueiri TK.

Future Oncol. 2008 Feb;4(1):85-92. doi: 10.2217/14796694.4.1.85. Review.

PMID:
18241003
13.

[The role of angiogenesis in renal carcinoma].

Bussolati B, Satolli MA, Camussi G.

G Ital Nefrol. 2008 May-Jun;25(3):297-305. Review. Italian.

PMID:
18473301
14.

Von Hippel-Lindau disease.

Sano T, Horiguchi H.

Microsc Res Tech. 2003 Feb 1;60(2):159-64. Review.

PMID:
12539169
15.
16.

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.

PMID:
12516032
17.

Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.

McDermott DF, George DJ.

Cancer Treat Rev. 2010 May;36(3):216-23. doi: 10.1016/j.ctrv.2009.12.003. Epub 2010 Jan 29. Review.

PMID:
20116176
18.

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.

Grothey A, Ellis LM.

Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de. Review.

PMID:
18536556
19.

VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.

Rini BI.

Curr Oncol Rep. 2006 Mar;8(2):85-9. Review.

PMID:
16507216
20.

Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.

Fernando NH, Hurwitz HI.

Semin Oncol. 2003 Jun;30(3 Suppl 6):39-50. Review.

PMID:
12802794

Supplemental Content

Support Center